Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 10/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29152851 | 0.86 | CDK2 (0.50) | CDK2CCNA2CCNA1CHEK1PDE10A | |
| SCHEMBL12953163 | 0.85 | CDK2 (0.49) | CDK2CCNA2CCNA1CHEK1PDE10A | |
| SCHEMBL30758 | 0.82 | CHEK1 (0.60) | CDK2CCNA2CCNA1CHEK1PDE10A | |
| SCHEMBL583594 | 0.78 | CHEK1 (0.38) | CDK2CCNA2CCNA1CHEK1PDE10A | |
| SCHEMBL584533 | 0.78 | HPGD (0.39) | CDK2CCNA2CCNA1CHEK1PDE10A | |
| SCHEMBL14545219 | 0.76 | CHEK1 (0.39) | CDK2CCNA2CCNA1CHEK1PDE10A | |
| SCHEMBL16784469 | 0.75 | CHEK1 (0.73) | CDK2CCNA2CCNA1CHEK1CDK1 | |
| SCHEMBL2679820 | 0.75 | PDE10A (0.41) | CDK2CCNA2CCNA1CHEK1PDE10A | |
| SCHEMBL14413453 | 0.73 | CHEK1 (0.39) | CDK2CCNA2CCNA1CHEK1RAD52 | |
| SCHEMBL1024592 | 0.72 | PDE10A (0.37) | CDK2CCNA2CCNA1CHEK1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448942-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8609675-B2 | Fused Tricyclic Compounds as novel mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| EP-2448942-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | Schering Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002887-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | SCHERING CORPORATION (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | CDK2 31/4885CCNA2 203/4885CCNA1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.